CrushSCI.com
68.8平均天数
73.5中位天数
19最短天数
120最长天数
622025发文量

Paper Review Records

全部论文审稿周期

18 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期;保留 PDF/DOI/网页源链接

72 天

Population Reference Data in the Molecular Diagnosis of Pathogenic CAPN3 Variants: Contextual Evidence and Interpretive Limits

作者
Meghan H. Carr; Ehab Y. Harahsheh; Shaymaa Shurrab; Bukola A. Olarewaju; Mayowa A. Osundiji展开收起
作者单位
1. Omics Curation Ltd., Hayes, UK; 2. Department of Neurology, Mayo Clinic, Phoenix, USA; 3. Division of Genetics/Metabolics, McMaster University, Hamilton, Canada; 4. School of Science and Engineering, University of Dundee, Dundee, UK; 5. Department of Clinical Genomics, Mayo Clinic, Phoenix, USA; 6. Prism Biomedical Consulting, Niagara Falls, Canada展开收起
PDF源文件 DOI 网页
35 天

Orca-T: First Approval

作者
Hannah A. Blair展开收起
作者单位
1. Springer Nature, Auckland, New Zealand展开收起
PDF源文件 DOI 网页
82 天

Rapid Ex Vivo Visualization of Laryngeal Tumors Using a Sprayable pH-Activatable Fluorophore

作者
Daan G. J. Linders; Sebastiaan W. R. Dalmeijer; Bo E. Zweedijk; Hamed Abbasi; Danielle Boldewijn; Sjors A. Koppes; Bernd Kremer; Jacobus Burggraaf; Denise E. Hilling; Joost R. van der Vorst; Jinhui Ser; Satoshi Kashiwagi; Maged Henary; Jeroen C. Jansen; Alexander L. Vahrmeijer; Hak Soo Choi; Stijn Keereweer展开收起
作者单位
1. Department of Otorhinolaryngology and Head and Neck Surgery, Leiden University Medical Center, Leiden, The Netherlands; 2. Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands; 3. Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands; 4. Department of Pathology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands; 5. Centre for Human Drug Research, Leiden, The Netherlands; 6. Leiden Academic Center for Drug Research, Leiden University, Leiden, The Netherlands; 7. Department of Surgical Oncology and Gastrointestinal Surgery, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, The Netherlands; 8. Gordon Center for Medical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, USA; 9. Center for Inflammation Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, USA; 10. Department of Chemistry, Center of Diagnostics and Therapeutics, Georgia State University, Atlanta, USA展开收起
PDF源文件 DOI 网页
90 天

Bridging Biomarker Testing to Biomarker-Driven Targeted Therapy: Real-World ESR1 Mutation Testing Patterns and Prevalence in ER+, HER2− Metastatic Breast Cancer

作者
Chi-Yin Liao; Jincy John; Precious Anyanwu; Manali A. Bhave; Francois-Clement Bidard; Tyler Marquart; Francisco Sapunar; Aarti Chawla; Lindsay A. Williams展开收起
作者单位
1. Eli Lilly and Company, Indianapolis, USA; 2. Winship Cancer Institute of Emory University, Atlanta, USA; 3. Institut Curie, Paris, France展开收起
PDF源文件 DOI 网页
19 天

Anbalcabtagene Autoleucel: First Approval

作者
Arnold Lee展开收起
作者单位
1. Springer Nature, Auckland 0754, New Zealand展开收起
PDF源文件 DOI 网页
80 天

Development of a Point-of-Care Recombinase Polymerase Amplification Assay for Detection of Neisseria gonorrhoeae and Ceftriaxone-Resistance Associated penA Allele 60.001

作者
Xia Sun; Ying Fu; Yi Liu; Qiongyao Liu; Luxia Chen; Jiang Zhu; Xu’ai Lin; Hao Cheng; Stijn van der Veen展开收起
作者单位
1. Department of Infectious Diseases of the Second Affiliated Hospital of Zhejiang University School of Medicine, Department of Microbiology, School of Medicine, Zhejiang University, Hangzhou, China; 2. Zhejiang University-University of Edinburgh Institute, School of Medicine, Zhejiang University, Haining, China; 3. Department of Clinical Laboratory, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China; 4. Amp-Future Biotech, Changzhou, China; 5. Department of Dermatology and Venereology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China; 6. State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China展开收起
PDF源文件 DOI 网页

FAQ

Molecular Diagnosis & Therapy审稿要多久?

截至2026-11-18,CrushSCI 收录了 Molecular Diagnosis & Therapy 的 18 篇完整审稿记录。最快一篇从收稿到录用用了 19 天(Anbalcabtagene Autoleucel: First Approval,2026-07-10 收稿,2026-07-29 录用),最慢一篇用了 120 天;平均 68.8 天,中位数 73.5 天。

Expert Matching · Case Demo

把投稿要求,转成可验证的期刊方案

说清专业、时限和作者背景,CrushSCI 结合真实审稿样本,给出拟题方向、期刊初筛与周期判断。

我们会在半小时内回复。

CrushSCI 在线

客户询问

我是环境工程专业,需要一篇 SCI,希望 3 个月内见刊。没有基金,也没有大牛挂名,可以投哪些期刊?

CrushSCI回复

可以。先按 90 天时限做可行性筛选,同步查找无基金、无知名作者挂靠的典型论文案例,作为选刊依据。重点核对研究质量与期刊 scope。

拟题建议
《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》

样本口径2026 年最近 5 篇有效论文样本

平均审稿59.6 天

中位数65 天

Contact CrushSCI

联系 CrushSCI

留下手机号或微信号,我们将与你确认学术润色、结构优化或一对一辅导咨询需求。

我们会在半小时内回复。

当前选择:学术咨询服务

预留联系方式

也可以直接发送邮件至 leader@crushsci.com

手机号和微信号至少填写一项,仅用于本次咨询联系,不会公开。